Indian Journal of Pharmacy Practice logo
Submit
Indian Journal of Pharmacy PracticeACADEMIC PUBLISHING
Article

Antituberculosis Drug Induced Hepatitis: A Case- Report

1, 1, 1

  1. 1Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Piparia, Waghodia, Vadodara, Gujarat, INDIA.

CORRESPONDENCE

Priyanshi R Shah

Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Piparia, Waghodia, Vadodara, Gujarat, INDIA.

priyanshishah2312@ gmail.com

Volume 15, Issue 2 · pp. 144-147 · 2022 · DOI: 10.5530/ijopp.15.2.25

ABSTRACT

Isoniazid, Rifampin and Pyrazinamide are first line antituberculosis medication. Among them isoniazid and pyrazinamide inhibit mycolic acid synthesis and rifampicin inhibit RNA polymerase. They are potent hepatotoxic. These drugs metabolize in liver by CYP450 enzyme. The drug toxicity is differing in different individuals because in some individuals drug metabolize by different pathway. Apart from hepatotoxicity, there are some reported cases of antituberculosis drug induced cutaneous reaction and gastrointestinal disturbances. A 31-year-old female patient came to respiratory department with complain of breathlessness, chest pain, abdominal pain, weight loss and loss of appetite. She was diagnosed with tuberculosis two months. For that she was put on HRZE regimen. Her laboratory data showed she had hepatitis. After stopping potent hepatotoxic medication her laboratory data started to normalize and symptoms relived. For tuberculosis she was shifted to alternative regimen. To prevent adverse drug reaction close monitoring of patient and therapy is required.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Shah, P. R., Sajan, C., & Mistry, M. (2022). Antituberculosis Drug Induced Hepatitis: A Case- Report. Indian Journal of Pharmacy Practice, 15(2), 144-147. https://doi.org/10.5530/ijopp.15.2.25

    Copyright and licence

    © 2022 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CC BY 4.0